BNTX Quote, Financials, Valuation and Earnings

Moderna, Inc. has a net margin of -1.89% compared to BioNTech SE's net margin of -121.83%. BioNTech SE's return on equity of -3.01% beat Moderna, Inc.'s return on equity of -29.19%.

BioNTech SE has a consensus price target of $139.76, signalling upside risk potential of 29.46%. On the other hand Moderna, Inc. has an analysts' consensus of $41.60 which suggests that it could fall by -10.73%. Given that BioNTech SE has higher upside potential than Moderna, Inc., analysts believe BioNTech SE is more attractive than Moderna, Inc..

BioNTech SE has a beta of 1.488, which suggesting that the stock is 48.755% more volatile than S&P 500. In comparison Moderna, Inc. has a beta of 1.318, suggesting its more volatile than the S&P 500 by 31.821%.

BioNTech SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Moderna, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioNTech SE pays -- of its earnings as a dividend. Moderna, Inc. pays out -- of its earnings as a dividend.

BioNTech SE quarterly revenues are $1.8B, which are larger than Moderna, Inc. quarterly revenues of $678M. BioNTech SE's net income of -$33.5M is higher than Moderna, Inc.'s net income of -$826M. Notably, BioNTech SE's price-to-earnings ratio is 191.55x while Moderna, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNTech SE is 7.34x versus 9.32x for Moderna, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Novavax, Inc. has a net margin of -1.89% compared to BioNTech SE's net margin of -287.29%. BioNTech SE's return on equity of -3.01% beat Novavax, Inc.'s return on equity of --.

BioNTech SE has a consensus price target of $139.76, signalling upside risk potential of 29.46%. On the other hand Novavax, Inc. has an analysts' consensus of $12.89 which suggests that it could grow by 48.32%. Given that Novavax, Inc. has higher upside potential than BioNTech SE, analysts believe Novavax, Inc. is more attractive than BioNTech SE.

BioNTech SE has a beta of 1.488, which suggesting that the stock is 48.755% more volatile than S&P 500. In comparison Novavax, Inc. has a beta of 2.583, suggesting its more volatile than the S&P 500 by 158.251%.

BioNTech SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Novavax, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. BioNTech SE pays -- of its earnings as a dividend. Novavax, Inc. pays out -- of its earnings as a dividend.

BioNTech SE quarterly revenues are $1.8B, which are larger than Novavax, Inc. quarterly revenues of $70.4M. BioNTech SE's net income of -$33.5M is higher than Novavax, Inc.'s net income of -$202.4M. Notably, BioNTech SE's price-to-earnings ratio is 191.55x while Novavax, Inc.'s PE ratio is 4.91x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNTech SE is 7.34x versus 1.38x for Novavax, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Pfizer Inc. has a net margin of -1.89% compared to BioNTech SE's net margin of -9.34%. BioNTech SE's return on equity of -3.01% beat Pfizer Inc.'s return on equity of 10.84%.

BioNTech SE has a consensus price target of $139.76, signalling upside risk potential of 29.46%. On the other hand Pfizer Inc. has an analysts' consensus of $28.71 which suggests that it could grow by 4.9%. Given that BioNTech SE has higher upside potential than Pfizer Inc., analysts believe BioNTech SE is more attractive than Pfizer Inc..

BioNTech SE has a beta of 1.488, which suggesting that the stock is 48.755% more volatile than S&P 500. In comparison Pfizer Inc. has a beta of 0.472, suggesting its less volatile than the S&P 500 by 52.751%.

BioNTech SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Pfizer Inc. offers a yield of 6.28% to investors and pays a quarterly dividend of $0.43 per share. BioNTech SE pays -- of its earnings as a dividend. Pfizer Inc. pays out 126.47% of its earnings as a dividend.

BioNTech SE quarterly revenues are $1.8B, which are smaller than Pfizer Inc. quarterly revenues of $17.6B. BioNTech SE's net income of -$33.5M is higher than Pfizer Inc.'s net income of -$1.6B. Notably, BioNTech SE's price-to-earnings ratio is 191.55x while Pfizer Inc.'s PE ratio is 20.20x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNTech SE is 7.34x versus 2.49x for Pfizer Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Sanofi has a net margin of -1.89% compared to BioNTech SE's net margin of 36.7%. BioNTech SE's return on equity of -3.01% beat Sanofi's return on equity of 12.45%.

BioNTech SE has a consensus price target of $139.76, signalling upside risk potential of 29.46%. On the other hand Sanofi has an analysts' consensus of $57.68 which suggests that it could grow by 25.01%. Given that BioNTech SE has higher upside potential than Sanofi, analysts believe BioNTech SE is more attractive than Sanofi.

BioNTech SE has a beta of 1.488, which suggesting that the stock is 48.755% more volatile than S&P 500. In comparison Sanofi has a beta of 0.455, suggesting its less volatile than the S&P 500 by 54.501%.

BioNTech SE has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sanofi offers a yield of 4.76% to investors and pays a quarterly dividend of $2.20 per share. BioNTech SE pays -- of its earnings as a dividend. Sanofi pays out 66.53% of its earnings as a dividend. Sanofi's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

BioNTech SE quarterly revenues are $1.8B, which are smaller than Sanofi quarterly revenues of $12.2B. BioNTech SE's net income of -$33.5M is lower than Sanofi's net income of $4.5B. Notably, BioNTech SE's price-to-earnings ratio is 191.55x while Sanofi's PE ratio is 19.33x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for BioNTech SE is 7.34x versus 2.28x for Sanofi. Usually stocks with elevated PS ratios are considered overvalued.